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Coronavirus disease 2019 (COVID-19) due 
to a novel coronavirus (CoV-2) has rapidly spread 
worldwide, with over 110,7 million cases and 
2.4 million deaths have been reported globally as of 
February 25th, with 420,000 new cases and nearly 
10,000 new deaths reported over the last 24 hours [1]. 
Cardiac involvement in COVID-19 patients has been 
described and associated with worse outcomes [2] 
and atrial fibrillation (AF) has been correlated with 
ventilator use and increased mortality [3]. The aim 
of the present study was to assess the impact of AF 
at admission on outcome in all-comer COVID-19 
patients admitted to the Emergency Department 
of Modena University Hospital.
We retrospectively analyzed the patients 
diagnosed with COVID-19 pneumonia (symp-
toms, positive nasopharyngeal swab and typical 
radiological feature) admitted to the Emergency 
Department of Modena University Hospital from 
March the 16th to April the 15th 2020, after obtain-
ing local EC approval. Clinical data, including 
outcome, were extracted from medical records. 
12-lead ECGs with 25 mm/s and 1 mV/cm calibra-
tion and 0.05–150 Hz filter setting were recorded
and analyzed off-line. Continuous variables were
expressed as mean ± standard deviation while
categorical data were expressed as absolute values
and proportions. The Fisher exact test and the
t-test or the Mann–Whitney U test were applied
as appropriate. Survival curves were plotted using
the Kaplan–Meier method with log-rank test and
COX-regression model was applied. Analyses were
performed with SPSS, Statistical Package for Social 
Science) software (v26, SPSS Inc., Chicago, IL, 
USA). For all the statistical analyses, a two tailed 
p < 0.05 was considered significant. 
Atrial fibrillation patients (30/201, 14.9%) were 
older (78.5 ± 12.6 vs. 66.8 ± 14.4, p < 0.001), 
with a more complex cardiovascular history (hy-
pertension [86.7% vs. 51.2%, p < 0.001], coronary 
artery disease [CAD, 46.7% vs 12.4%, p < 0.001], 
peripheral artery disease [20.0% vs. 5.9%, 
p = 0.019] and chronic kidney disease [CKD 30.0% 
vs. 10.1%, p = 0.006]) and positive myocardial 
injury markers (troponin I 1042.7 ± 4534.5 vs. 
55.6 ± 172.3 ng/L). The mean CHA2DS2VASc score 
was 4.23 ± 1.71 vs. 2.27 ± 1.76, p < 0.001 (Fig. 1A). 
AF-patients presented a 5-fold higher risk of 
mortality (odds ratio [OR] 5.33, 95% confidence 
interval [CI] 2.34–12.17, p < 0.001), which rose 
12-fold (OR 12.74, 95% CI 3.65–44.48, p < 0.001)
for those with AF at 12-lead electrocardiogram
(ECG) at admission. Patients with the highest
CHA2DS2VASc score presented the highest rate of
mortality (Fig. 1B). After adjustment for confound-
ing factors such as age, sex, hypertension, CAD
and CKD, AF was confirmed to be an independent
predictor of all-cause mortality (hazard ratio 0.48,
95% CI 0.24–0.93, p = 0.030; Fig. 1C).
Electrocardiogram alterations, including AF, 
are quite common in COVID-19 infection and re-
lated to worse clinical outcome [4]. AF is detected 
in COVID-19 patients at 12-lead baseline ECG in 
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onset AF has been related to worse cardiovascular 
outcome [6]. These patients may benefit from 
a more intensive treatment for primary prevention 
of thrombo-embolic events, representing, among 
all cardiovascular-diseased COVID-19 patients, 
a high-risk group. Although further studies from 
larger population cohorts are required to assess the 
prognostic role of AF in COVID-19, these patients 
are potentially fragile and vulnerable, character-
ized by a higher risk of death, thus suitable for 
a careful clinical monitoring and more intensive 
treatment [7]. The CHA2DS2VASc score may be 
useful in further risk stratification of COVID-19 [8] 
and early identification of AF with routine ECG 
evaluation may be helpful in risk assessment and 
therapy approach individualization.  
As of today, COVID-19 infection treatment 
is based on supportive therapies and mechani-
cal ventilation. Despite our small cohort size, 
a higher 30-day mortality was observed in COVID-19 
patients with AF at baseline 12-lead ECG; thus, 
routine ECG evaluation, in COVID-19 pneumonia, 
may be helpful in risk stratification and therapeutic 
approach targeting.
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Figure 1. A. Baseline characteristics; B. 30-day mortality rate according to CHA2DS2VASc score in atrial fibrillation (AF)- 
and no-AF-patients; C. 30-day mortality according to presence/absence of AF after adjustment for age, sex, history 
of hypertension, coronary artery disease (CAD) and chronic kidney disease (CKD); PAD — peripheral artery disease; 
HR — hazard ratio; CI — confidence interval.
AF (n = 30) No-AF (n = 171) P value
Age 78.5 ± 12.6 66.8 ± 14.4 0.003
Female sex 40.0 35.1 0.681
Hypertension 86.7 51.2 < 0.001
Diabetes 33.3 15.9 0.038
CAD 46.7 12.4 < 0.001
PAD 20.0 5.9 0.019
CKD 30.0 10.1 0.006
SO2 90.7 ± 5.3 93.1 ± 4.4 0.009
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